<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39352022</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1756-185X</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>International journal of rheumatic diseases</Title><ISOAbbreviation>Int J Rheum Dis</ISOAbbreviation></Journal><ArticleTitle>Comparative outcome of patients with systemic autoimmune rheumatic disease affected by COVID-19 infection-An Asian perspective.</ArticleTitle><Pagination><StartPage>e15359</StartPage><MedlinePgn>e15359</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/1756-185X.15359</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Kuo-Tung</ForeName><Initials>KT</Initials><Identifier Source="ORCID">0000-0002-5468-1329</Identifier><AffiliationInfo><Affiliation>Division of Allergy, Immunology, and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ph.D. Program in Translational Medicine and RongHsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>105-2320-B-005-006</GrantID><Agency>Ministry of Science and Technology, Taiwan</Agency><Country /></Grant><Grant><GrantID>TCVGH-1123801C</GrantID><Agency>Taichung Veterans General Hospital</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Rheum Dis</MedlineTA><NlmUniqueID>101474930</NlmUniqueID><ISSNLinking>1756-1841</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012216" MajorTopicYN="Y">Rheumatic Diseases</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>8</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39352022</ArticleId><ArticleId IdType="doi">10.1111/1756-185X.15359</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Conway R, Grimshaw AA, Konig MF, et al. SARS‐CoV‐2 infection and COVID‐19 outcomes in rheumatic diseases: a systematic literature review and meta‐analysis. Arthritis &amp; Rhematology. 2022;74(5):766‐775.</Citation></Reference><Reference><Citation>Chen DY, Huang PI, Kuo‐Tung T. Characteristics of long COVID in patients with autoimmune rheumatic diseases: a systematic review and meta‐analysis. Rheumatol Adv Pract. 2024;8:rkae027.</Citation></Reference><Reference><Citation>Tang KT, Hsu BC, Chen DY. Immunogenicity, effectiveness, and safety of COVID‐19 vaccines in rheumatic patients: an updated systematic review and meta‐analysis. Biomedicine. 2022;10(4):834.</Citation></Reference><Reference><Citation>Patel NJ, Cook C, Vanni K, et al. Impact of vaccination on postacute sequelae of SARS CoV‐2 infection in patients with rheumatic diseases. Annals of the Rheumatic Diseases. 2023;82(4):565‐573.</Citation></Reference><Reference><Citation>Qian G, Wang X, Patel NJ, et al. Outcomes with and without outpatient SARS‐CoV‐2 treatment for patients with COVID‐19 and systemic autoimmune rheumatic diseases: a retrospective cohort study. Lancet Rheumatol. 2023;5(3):e139‐e150.</Citation></Reference><Reference><Citation>Gerolymatou N, Bakasis AD, Voulgari PV. Vlachoyiannopoulos PG Oral antiviral treatment for COVID‐19 in patients with systemic autoimmune rheumatic diseases. The Journal of Rheumatology. 2023;50(8):1078‐1081.</Citation></Reference><Reference><Citation>Izadi Z, Gianfrancesco MA, Schmajuk G, et al. Environmental and societal factors associated with COVID‐19‐related death in people with rheumatic disease: an observational study. Lancet Rheumatol. 2022;4(9):e603‐e613.</Citation></Reference><Reference><Citation>Mathieu E, Ritchie H, Ortiz‐Ospina E, et al. A global database of COVID‐19 vaccinations. Nature Human Behaviour. 2021;5(7):947‐953.</Citation></Reference><Reference><Citation>Chen M, Wei Y, Zhang Q, Wan Q, Chen X. Epidemiology and clinical characteristics of COVID‐19 in rheumatic diseases at a tertiary care hospital in Wuhan, China. Clinical and Experimental Rheumatology. 2021;39(2):442‐443.</Citation></Reference><Reference><Citation>So H, Mak JW‐Y, So J, et al. Incidence and clinical course of COVID‐19 in patients with rheumatologic diseases: a population‐based study. Seminars in Arthritis and Rheumatism. 2020;50(5):885‐889.</Citation></Reference><Reference><Citation>Huang Y, Chen Z, Wang Y, et al. Clinical characteristics of 17 patients with COVID‐19 and systemic autoimmune diseases: a retrospective study. Annals of the Rheumatic Diseases. 2020;79(9):1163‐1169.</Citation></Reference><Reference><Citation>Shin YH, Shin JI, Moon SY, et al. Autoimmune inflammatory rheumatic diseases and COVID‐19 outcomes in South Korea: a nationwide cohort study. Lancet Rheumatol. 2021;3(10):e698‐e706.</Citation></Reference><Reference><Citation>Oku K, Kimoto Y, Horiuchi T, et al. Risk factors for hospitalization or mortality for COVID‐19 in patients with rheumatic diseases: results of a nationwide JCR COVID‐19 registry in Japan. Modern Rheumatology. 2023;33(4):768‐776.</Citation></Reference><Reference><Citation>Mathew J, Jain S, Susngi T, et al. Predictors of COVID‐19 severity and outcomes in Indian patients with rheumatic diseases: a prospective cohort study. Rheumatol Adv Pract. 2023;7(1):rkad025.</Citation></Reference><Reference><Citation>Gianfrancesco MA, Leykina LA, Izadi Z, et al. Association of Race and Ethnicity with COVID‐19 outcomes in rheumatic disease: data from the COVID‐19 global rheumatology Alliance physician registry. Arthritis &amp; Rhematology. 2021;73(3):374‐380.</Citation></Reference><Reference><Citation>Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID‐19‐related death using OpenSAFELY. Nature. 2020;584(7821):430‐436.</Citation></Reference><Reference><Citation>Chang R, Yen‐Ting Chen T, Wang SI, Hung YM, Chen HY. Wei CJ risk of autoimmune diseases in patients with COVID‐19: a retrospective cohort study. EClinicalMedicine. 2023;56:101783.</Citation></Reference><Reference><Citation>Budd J, Miller BS, Manning EM, et al. Digital technologies in the public‐health response to COVID‐19. Nature Medicine. 2020;26(8):1183‐1192.</Citation></Reference><Reference><Citation>Sandhu A, Agarwal A, Kaur P, et al. Evaluation of tele‐rheumatology during the COVID‐19 pandemic in Asian population: a pilot study. International Journal of Telemedicine and Applications. 2021;2021:5558826.</Citation></Reference><Reference><Citation>So H, Szeto CC, Tam LS. Patient acceptance of using telemedicine for follow‐up of lupus nephritis in the COVID‐19 outbreak. Annals of the Rheumatic Diseases. 2021;80(6):e97.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>